Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells

Endocrinology

Volumn 140, Issue 11, 1999, Pages 5054-5059

  Lu, S ^a   Tsai, S Y ^a   Tsai, M J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0033303702     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.11.7086     Document Type: Article

References (26)

1. Cancer statistics
2. Androgen receptor in human prostate cancer: Heterogeneous expression, gene mutations, and polymorphic variants
3. Role of androgens in prostatic cancer
4. Carcinoma of the bladder and prostate
5. The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity
6. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
7. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
8. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
9. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
10. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
11. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
12. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3
13. In vitro model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells
14. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer
15. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
16. Androgen regulation of programmed death of normal and malignant prostatic cells
17. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells
18. Androgen regulation of the CDK inhibitor p21 gene through an ARE in the proximal promoter
19. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes
20. Deletional, mutational, and methylation analysis of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
21. p53, the cellular gatekeeper for growth and division
22. Resistance to apoptosis conferred by CDK inhibitors during myocyte differentiation
23. p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells
24. Activation of cyclin A-dependent protein kinases during apoptosis
25. Cleavage of p21(Cip1/Waf1) and p27(Kip1) mediates apoptosis in endothelial cells through activation of CDK2: Role of a caspase cascade
26. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins